Search | Clinical Trials Finder

Conditions: Healthy
Interventions: Rosuvastatin, Clopidogrel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Coronary Artery Disease
Interventions: statin, evolocumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Anaemia
Interventions: GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Midazolam, Rosuvastatin, CKD-508 Tablet; Drug
Lead sponsor: Chong Kun Dang Pharmaceutical; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: ARV-471, Rosuvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and stable statin therapy, Stable statin therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 13
States / cities: Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more

Conditions: COVID-19
Interventions: EDP-235, Midazolam, Rosuvastatin, Caffeine; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: MK-0616A, Enlicitide, Rosuvastatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Participants
Interventions: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Coronary Atherosclerosis
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 97
States / cities: Huntsville, Alabama • Los Angeles, California • Mountain View, California + 94 more

Conditions: Rheumatoid Arthritis
Interventions: Atorvastatin, Pravastatin, Rosuvastatin, Filgotinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy Participants
Interventions: Digoxin, Rosuvastatin, Metformin, Povorcitinib, Probenecid; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: Placebo, PF-04950615 (RN316); Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more

Conditions: Interaction Drug Food
Interventions: goldenseal, Metformin, Furosemide, Midazolam oral solution, Rosuvastatin Oral Tablet; Dietary Supplement · Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Hypercholesterolaemia
Interventions: Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Advanced Solid Tumor
Interventions: Sitravatinib, Warfarin, Dextromethorphan, Midazolam, Digoxin, Rosuvastatin, Nivolumab; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Goshen, Indiana • Austin, Texas • San Antonio, Texas + 2 more

Conditions: Healthy
Interventions: LY3537982, Digoxin, Rosuvastatin, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: RSV Infection
Interventions: EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Lipid Disorder
Interventions: moderate- or high-intensity statin/ rosuvastatin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Type 2 Diabetes
Interventions: Lapaquistat acetate and lipid-lowering therapy, Lipid-lowering therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: Tucson, Arizona • Artesia, California • Jacksonville, Florida + 15 more

Conditions: Obesity
Interventions: Danuglipron, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Anaheim, California • South Miami, Florida

Conditions: Cholesterol; Lipidosis
Interventions: Rosuvastatin 10mg; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Healthy
Interventions: Rosuvastatin, Furosemide, MK-2828; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 24 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

Drug Interaction Study of Clopidogrel and Rosuvastatin

Rosuvastatin and Evolocumab for Coronary Artery Disease

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

CRESTOR Athero Imaging Head to Head IVUS Study

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

Liver Adiposity Effects on Pediatric Statin

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)